Department of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China.
Priority Research Centre for Asthma and Respiratory Diseases, Hunter Medical Research Institute and the University of Newcastle, Newcastle, NSW, 2305, Australia.
Stem Cell Res Ther. 2021 Mar 24;12(1):204. doi: 10.1186/s13287-021-02244-6.
Severe, steroid-resistant asthma (SSRA) is a serious clinical problem in asthma management. Affected patients have severe clinical symptoms, worsened quality of life, and do not respond to steroid, a mainstay steroid treatment of asthma. Thus, effective therapies are urgently needed. Exosomes derived from mesenchymal stem cell (MSC-Exo) has become attractive candidates for the lung inflammatory diseases through its immunomodulatory effects. In this study, we explored the therapeutic effects of MSC-Exo in SSRA and identified the therapeutic mechanism of MSC-Exo.
Exosomes from human umbilical cord mesenchymal stem cell (hUCMSC) were isolated and characterized by transmission electron microscopy, nanoparticle tracking analysis and flow cytometry analysis. Effects of MSC-Exo on airway hyper responsiveness (AHR), inflammation, histopathology, and macrophage polarization in SSRA in mice were evaluated. Systematic depletion of macrophages determined the role of macrophages in the therapeutic effect of SSRA in mice. LPS-stimulated RAW 264.7 cell model was constructed to determine the underlying mechanism of MSC-Exo on macrophage polarization. qRT-PCR, Western blotting, immunofluorescence, and flow cytometry were performed to evaluate the expression of M1 or M2 markers. Tandem mass tags (TMT)-labeled quantitative proteomics were applied to explore the central protein during the regulation effect of MSC-Exo on macrophage polarization. Knockdown and overexpression of TRAF1 were used to further clarify the role of the central protein on macrophage polarization.
We successfully isolated and characterized exosomes from hUCMSCs. We verified that the intratracheal administration of MSC-Exo reversed AHR, histopathology changes, and inflammation in SSRA mice. Systematic depletion of macrophages weakened the therapeutic effect of MSC-Exo. We found that MSC-Exo treatment inhibited M1 polarization and promoted M2 polarization in LPS-stimulated RAW 264.7 cells. Subsequently, tumor necrosis factor receptor-associated factor 1 (TRAF1) was determined as the central protein which may be closely related to the regulation of macrophage polarization from TMT-labeled quantitative proteomics analysis. Knockdown and overexpression of TRAF1 demonstrated that the effect of MSC-Exo treatment on macrophage polarization, NF-κB and PI3K/AKT signaling was dependent on TRAF1.
MSC-Exo can ameliorate SSRA by moderating inflammation, which is achieved by reshaping macrophage polarization via inhibition of TRAF1.
严重的、类固醇耐药性哮喘(SSRA)是哮喘管理中的一个严重临床问题。受影响的患者有严重的临床症状,生活质量恶化,并且对哮喘的主要类固醇治疗反应不佳。因此,迫切需要有效的治疗方法。间充质干细胞(MSC)衍生的外泌体通过其免疫调节作用成为肺部炎症性疾病的有吸引力的候选物。在这项研究中,我们探讨了 MSC-Exo 在 SSRA 中的治疗效果,并确定了 MSC-Exo 的治疗机制。
分离并鉴定人脐带间充质干细胞(hUCMSC)来源的外泌体,透射电子显微镜、纳米颗粒跟踪分析和流式细胞术分析。评价 MSC-Exo 对 SSRA 小鼠气道高反应性(AHR)、炎症、组织病理学和巨噬细胞极化的影响。系统耗竭巨噬细胞确定了巨噬细胞在 SSRA 小鼠治疗中的作用。构建 LPS 刺激的 RAW 264.7 细胞模型,以确定 MSC-Exo 对巨噬细胞极化的潜在机制。qRT-PCR、Western blot、免疫荧光和流式细胞术用于评估 M1 或 M2 标志物的表达。串联质量标签(TMT)标记定量蛋白质组学用于探索 MSC-Exo 调节巨噬细胞极化的中心蛋白。用 TRAF1 的敲低和过表达进一步阐明中心蛋白在巨噬细胞极化中的作用。
我们成功地从 hUCMSCs 中分离并鉴定了外泌体。我们验证了气管内给予 MSC-Exo 可逆转 SSRA 小鼠的 AHR、组织病理学改变和炎症。系统耗竭巨噬细胞减弱了 MSC-Exo 的治疗效果。我们发现 MSC-Exo 治疗抑制了 LPS 刺激的 RAW 264.7 细胞中 M1 极化,并促进了 M2 极化。随后,通过 TMT 标记定量蛋白质组学分析,确定肿瘤坏死因子受体相关因子 1(TRAF1)为中心蛋白,该蛋白可能与调节巨噬细胞极化密切相关。TRAF1 的敲低和过表达表明,MSC-Exo 治疗对巨噬细胞极化、NF-κB 和 PI3K/AKT 信号的影响依赖于 TRAF1。
MSC-Exo 通过调节炎症改善 SSRA,这是通过抑制 TRAF1 重塑巨噬细胞极化来实现的。